文献速递骨质疏松与钙磷/甲状旁腺

循环miR-181c-5p和miR-497-5p是骨质疏松症预后与诊断的潜在生物标志物

Circulating miR-181c-5p and miR-497-5p Are Potential Biomarkers for Prognosis and Diagnosis of Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究通过基因芯片和实时PCR筛选骨质疏松女性骨组织中差异表达的miRNA,并在验证队列中检测血清水平。发现miR-181c-5p和miR-497-5p在骨质疏松或骨量减少的绝经后女性血清中降低,而在双膦酸盐联合骨化三醇治疗者中升高;动物和细胞实验提示其参与骨代谢,可能作为监测抗骨质疏松疗效或诊断方法的潜在生物标志物。

要点

  • 在21例60-69岁和80-89岁骨质疏松女性骨组织中筛选出24个高差异表达miRNA。
  • 验证队列中,miR-181c-5p和miR-497-5p在骨量减少或骨质疏松的绝经后女性血清中降低,在双膦酸盐联合骨化三醇治疗者中升高。
  • 过表达miR-181c-5p和miR-497-5p促进成骨细胞分化和矿化。

核心结论

  • miR-181c-5p和miR-497-5p参与骨代谢,并与骨质疏松导致的进行性骨丢失相关,提示循环miR-181c-5p和miR-497-5p可能作为监测抗骨质疏松治疗疗效或诊断方法的潜在生物标志物。

研究设计与样本

  • 研究使用基因芯片和实时PCR筛查21例60-69岁和80-89岁骨质疏松女性骨组织中的差异表达miRNA,并在由14例健康绝经前女性和86例骨量减少或骨质疏松的绝经后女性组成的验证队列中检测血清miRNA。
  • 在衰老和OVX小鼠模型及成骨细胞中验证miR-181c-5p和miR-497-5p的表达,并在体外验证其在成骨中的作用。

主要发现

  • 初始筛查中,24个miRNA在骨质疏松女性骨组织中显示最高差异表达,其中4个miRNA在验证队列的骨组织和血清中均被鉴定到。
  • miR-181c-5p和miR-497-5p在骨量减少或骨质疏松的绝经后女性血清中水平降低,但在接受双膦酸盐联合骨化三醇治疗的受试者中水平升高。
  • 在衰老和OVX小鼠模型的骨组织中,miR-181c-5p和miR-497-5p显著下调,而在hFOB1.19和MC3T3-E1细胞成骨分化过程中上调。
  • 过表达miR-181c-5p和miR-497-5p促进成骨细胞的分化和矿化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Osteoporosis is a degenerative bone disease in aging men and women. MiRNAs associated with progressive bone loss in osteoporosis had not been clearly demonstrated. OBJECTIVE: The evaluation of the differentially expressed miRNAs in the bone tissue and serum of osteoporotic women with aging. METHODS: MiRNAs GeneChip and real-time PCR were used to screen differently expressed miRNAs in bone tissues of 21 osteoporotic women ages 60-69 years and 80-89 years. Identified miRNAs were detected in the serum of the validation cohort, which consisted of 14 healthy premenopausal women and 86 postmenopausal women with osteopenia or osteoporosis. MiR-181c-5p and miR-497-5p expression were validated in aging and OVX mice models, and osteoblasts. Their role in osteogenesis was validated in vitro. RESULTS: Twenty-four miRNAs showed the highest differential expression in bone tissues of osteoporotic women in initial screening. Among them, four miRNAs were identified both in the bone tissue and serum in the validation cohort. The levels of miR-181c-5p and miR-497-5p were decreased in the serum of postmenopausal women with osteopenia or osteoporosis, but increased in subjects treated with bisphosphonate plus calcitriol. MiR-181c-5p and miR-497-5p were significantly downregulated in the bone tissue of aging and OVX mice models, and upregulated during the osteogenic differentiation of hFOB1.19 and MC3T3-E1 cells. Overexpression of miR-181c-5p and miR-497-5p promoted the differentiation and mineralization of osteoblasts. CONCLUSIONS: MiR-181c-5p and miR-497-5p are involved in bone metabolism and associated with progressive bone loss of due to osteoporosis, suggesting that circulating miR-181c-5p and miR-497-5p might act as potential biomarkers for monitoring the effects of antiosteoporotic therapies or the diagnostic approach.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ma J, Lin X, Chen C, et al. Circulating miR-181c-5p and miR-497-5p Are Potential Biomarkers for Prognosis and Diagnosis of Osteoporosis. J Clin Endocrinol Metab. 2020. PMID: 31872255. doi:10.1210/clinem/dgz300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。